# A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes

Study · id `cardio:ct-nct02017171` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02017171](<https://clinicaltrials.gov/study/NCT02017171>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02017171

Browse, organ or system: Heart; Kidneys; Metabolism  
Browse, condition area: Coronary and vascular disease; Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 530 participants.

## Technical summary

Registry record NCT02017171. Randomized; triple masking; primary purpose prevention. Start 2014-02 (actual); primary completion 2019-07-15 (actual). Results posted on 2020-11-20.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 530 participants (enrolled count; ClinicalTrials.gov record NCT02017171, source copy `cardio:ctgov-nct02017171-2020-12-04`, retrieved 2026-10-26)
- Started: 2014-02 (actual) (ClinicalTrials.gov record NCT02017171, source copy `cardio:ctgov-nct02017171-2020-12-04`, retrieved 2026-10-26)
- Primary completion: 2019-07-15 (actual) (ClinicalTrials.gov record NCT02017171, source copy `cardio:ctgov-nct02017171-2020-12-04`, retrieved 2026-10-26)
- Completion: 2019-08-31 (actual) (ClinicalTrials.gov record NCT02017171, source copy `cardio:ctgov-nct02017171-2020-12-04`, retrieved 2026-10-26)
- Results first posted: 2020-11-20 (ClinicalTrials.gov record NCT02017171, source copy `cardio:ctgov-nct02017171-2020-12-04`, retrieved 2026-10-26)
- Countries: United States; Canada; Denmark (ClinicalTrials.gov record NCT02017171, source copy `cardio:ctgov-nct02017171-2020-12-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02017171-2020-12-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
- Condition: Diabetic Nephropathies
- Condition: Coronary Artery Disease
- Intervention (Drug): Allopurinol
- Intervention (Drug): Placebo
- Lead sponsor: Alessandro Doria
- Lead sponsor class: OTHER
- Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Collaborator class: NIH
- Collaborator: Juvenile Diabetes Research Foundation
- Collaborator class: OTHER
- Collaborator: Joslin Diabetes Center
- Collaborator class: OTHER
- Collaborator: University of Minnesota
- Collaborator class: OTHER
- Collaborator: University of Colorado, Denver
- Collaborator class: OTHER
- Collaborator: University of Michigan
- Collaborator class: OTHER
- Collaborator: University of Toronto
- Collaborator class: OTHER
- Collaborator: Northwestern University
- Collaborator class: OTHER
- Collaborator: Albert Einstein College of Medicine
- Collaborator class: OTHER
- Collaborator: Steno Diabetes Center Copenhagen
- Collaborator class: OTHER
- Collaborator: Washington University School of Medicine
- Collaborator class: OTHER
- Collaborator: University of Washington
- Collaborator class: OTHER
- Collaborator: Emory University
- Collaborator class: OTHER
- Collaborator: University of Calgary
- Collaborator class: OTHER
- Collaborator: University of Alberta
- Collaborator class: OTHER
- Collaborator: University of Texas Southwestern Medical Center
- Collaborator class: OTHER
- Collaborator: BCDiabetes.Ca
- Collaborator class: NETWORK

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as a collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (`cardio:niddk`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes (`cardio:pubmed-32579810`)

Courtesy of the U.S. National Library of Medicine.

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 14 registry organizations

## Provenance

Content hash: a0f519d97a978d565273378c33d1bb4933ed3a0052674e1581e1c3d03f7bb14b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
